Several reports have described that selegiline, a monoamine oxidase B (MAO-B) inhibitor, is effective for the treatment of decreased willingness and depressed mood in PD.Tom and Cummings[32] recommended selegiline as the first choice to treat depression in PD patients not exhibiting suicidality. Here, MAOB is linked to depressive symptom measurement.